MAIN POST Major Depressive Disorder in Older Adults Major depressive disorder (MDD) in older adults often presents differently than in younger populations, with a greater prominence of fatigue, social withdrawal, and somatic complaints. These atypical features may contribute to delayed recognition and complicate clinical decision-making in routine practice. For psychiatric–mental health nurse practitioners (PMHNPs), this underscores the importance of developing treatment plans that effectively address depressive symptoms while prioritizing safety, tolerability, and the unique needs of the elderly population. Pharmacological Therapy Approved by the FDA Selective serotonin reuptake inhibitors (SSRIs) are widely recommended as first-line, FDA-approved pharmacologic treatments for major depressive disorder in older adults. Evidence indicates that SSRIs are both effective and generally better tolerated than older antidepressants, largely due to their lower anticholinergic burden (IsHak et al., 2025). Among this class, sertraline and escitalopram are frequently preferred because of their favorable dosing flexibility and tolerability profiles. The benefits of SSRIs include improvement in mood, reduction in functional impairment, and a relatively predictable side-effect profile. However, careful risk assessment remains essential in geriatric populations. Clinicians must monitor for potential adverse effects such as hyponatremia, gastrointestinal disturbances, increased fall risk, and possible drug–drug interactions with existing medications. Implementing thorough medication reconciliation and obtaining baseline laboratory studies are important strategies to reduce preventable complications in older adults. Off-Label Pharmacological Choice A subset of older adults continues to experience significant depressive symptoms despite adequate trials of FDA-approved antidepressants. In such cases, off-label treatment strategies may be considered. Larsen et al. (2025) highlight augmentation with agents such as aripiprazole and the use of ketamine-based therapies as potential options for managing treatment-resistant depression. These approaches may offer benefits, including more rapid symptom relief and improved functional outcomes when conventional treatments are ineffective. However, the risk profile of these interventions is more complex in geriatric populations. Aripiprazole may increase the risk of metabolic disturbances and extrapyramidal symptoms, while ketamine is associated with concerns such as transient increases in blood pressure, dissociative effects, and uncertainties regarding long-term safety. Consequently, the use of these treatments requires comprehensive patient screening, close monitoring, and shared decision-making to ensure safety and optimize outcomes in older adults with complex psychiatric needs. Non pharmacological Intervention Non Pharmacological interventions play a central role in the management of depression among older adults. Evidence suggests that structured social support interventions can significantly reduce depressive symptoms and improve overall quality of life, particularly by addressing social isolation through group activities, peer engagement, and caregiver involvement (Faronbi et al., 2025). These approaches are further supported by psychotherapeutic modalities. For example, behavioral activation and group-based psychotherapy have demonstrated meaningful symptom improvement in community-dwelling older adults (Morgado et al., 2024). In addition, exercise-based interventions have been shown to enhance mood, reduce anxiety, and improve overall well-being, while posing minimal risk to this population (Soong et al., 2025). When integrated, these nonpharmacological strategies complement pharmacologic treatments and promote resilience, autonomy, and functional recovery in later-life depression. Ongoing risk assessment remains essential, as treatment plans should be continuously adjusted in response to changes in physical health, cognitive status, and available social support systems. Conclusion The management of major depressive disorder in older adults requires an individualized, multimodal approach rather than a standardized treatment strategy. Newer antidepressants are appropriate as first-line interventions, while alternative or augmentation strategies may be necessary in cases of treatment resistance. Nonpharmacological interventions—including social support, psychotherapy, and exercise—are also essential components of comprehensive care. By integrating current evidence, patient preferences, and ongoing risk assessment, psychiatric–mental health nurse practitioners (PMHNPs) can deliver care that is both safe and responsive to the evolving needs of the patient. This balanced approach supports symptom remission and promotes the preservation of quality of life in the geriatric population. References Faronbi, J. O., Eromosele, B., Fawole, H. O., Idowu, O. A., Akinrolie, O., Akinsulore, A., Adeniji, T., Ibekaku, M. C., Oyinlola, O., Faronbi, G. O., & Mbada, C. (2025). Effects of social support interventions on depressive symptoms and quality of life among older adults: A systematic review and meta-analysis. BMC Geriatrics, 25(1). https://doi.org/10.1186/s12877-025-06146-7Links to an external site. IsHak, W. W., Hirsch, D., Renteria, S., Totlani, J., Murphy, N., Chang, T., Abdelsalam, R., Salem, M., Meyer, A., Keerthana, S., Liu, A., Contreras, L., Tadros, E., Hedrick, R., Danovitch, I., & Pechnick, R. N. (2025). Depressive disorders: Systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications. BMC Psychiatry, 25(1). https://doi.org/10.1186/s12888-025-07141-3Links to an external site. Larsen, A. J., Teobaldi, G., Espinoza Jeraldo, R. I., Falkai, P., & Cooper, C. (2025). Effectiveness of pharmacological and non-pharmacological interventions for treatment-resistant depression in older patients: A systematic review and meta-analysis. BMJ Mental Health, 28(1), e301324. https://doi.org/10.1136/bmjment-2024-301324Links to an external site. Morgado, B., Silva, C., Agostinho, I., Brás, F., Amaro, P., Lusquinhos, L., Silva, M. R., Fonseca, C., Albacar-Riobóo, N., & Guedes de Pinho, L. (2024). Psychotherapeutic interventions for depressive symptoms in community-dwelling older adults: A systematic review with meta-analysis. Healthcare, 12(24), 2551. https://doi.org/10.3390/healthcare12242551Links to an external site. Soong, R. Y., Low, C. E., Ong, V., Sim, I., Lee, C., Lee, F., Chew, L., Yau, C. E., Lee, A. R., & Chen, M. Z. (2025). Exercise interventions for depression, anxiety, and quality of life in older adults with cancer. JAMA Network Open, 8(2), e2457859. https://doi.org/10.1001/jamanetworkopen.2024.57859Links to an external site.